Economic burden and risk of cardiovascular disease and diabetes in patients with different cardiometabolic risk profiles

被引:16
作者
Caro, J. Jaime
O'Brien, Judith A.
Hollenbeak, Christopher S.
Spackman, Eldon
Ben-Joseph, Rami
Okamoto, Lynn J.
Paramore, L. Clark
机构
[1] Caro Res, Concord, MA 01742 USA
[2] Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA
[3] United BioSource Corp, Ctr Hlth Econ & Policy, Bethesda, MD USA
[4] Sanofi Aventis, Bridgewater, NJ USA
关键词
burden; costs; diabetes; metabolic risk; DIRECT MEDICAL COSTS; METABOLIC SYNDROME; LIFE EXPECTANCY; HEALTH-CARE; MELLITUS; OBESITY; OVERWEIGHT; MORTALITY; SURVIVAL; OUTCOMES;
D O I
10.1111/j.1524-4733.2006.00150.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: The long-term risk of cardiovascular disease and diabetes have not been modeled for individuals with metabolic syndrome or other related cardiometabolic risk factors, nor have their long-term costs been estimated. Therefore, we used a Markov model to estimate these risks and costs over a decade. Methods: A Markov model was used to predict the development of diabetes and cardiovascular events myocardial infarction [MI], stroke) in cohorts according to their specific risk factor profiles. Six risk factors profiles were based on adults (18 years and older) in the NHANES 2001-2002 database. These profiles were combined with risk equations to estimate transition probabilities for the Markov model. Costs of both acute (MI, stroke) and chronic (MI, stroke, diabetes) management were estimated based on all-payer discharge data, insurance claims data, government sources, and the published literature. Results: The model estimated that approximately 11% and 23% of individuals within the National Cholesterol Education Program Adult Treatment Panel III metabolic syndrome risk cohort would have new onset of diabetes within 3 years and 7 years, respectively. By year 10, the risk of developing diabetes was 31% for the metabolic syndrome risk cohort, and the risk of an incident acute MI or stroke event was approximately 3% to 4%. Cumulative costs as a result of new onset of diabetes within 10 years were estimated at $6200 per individual in the metabolic syndrome cohort and $20,000 per patient within the cohort who developed diabetes. The corresponding costs for incident acute MI and stroke were estimated at $2200 and $1300, respectively, per individual in the cohort, and $55,000 and $37,000, respectively, per patient in the cohort who had an event. Conclusion: Based on the results of these analyses, individuals with cardiometabolic risk factors such as those comprising the metabolic syndrome are expected to have a substantial risk for cardiovascular events and conditions. In addition, these individuals can be expected to place a considerable economic burden on the health-care system even in the short term.
引用
收藏
页码:S12 / S20
页数:9
相关论文
共 33 条
  • [1] The metabolic syndrome - a new worldwide definition
    Alberti, KGMM
    Zimmet, P
    Shaw, J
    [J]. LANCET, 2005, 366 (9491) : 1059 - 1062
  • [2] CARDIOVASCULAR-DISEASE RISK PROFILES
    ANDERSON, KM
    ODELL, PM
    WILSON, PWF
    KANNEL, WB
    [J]. AMERICAN HEART JOURNAL, 1991, 121 (01) : 293 - 298
  • [3] [Anonymous], NAT AMB MED CAR SURV
  • [4] Obesity and the use of health care services
    Bertakis, KD
    Azari, R
    [J]. OBESITY RESEARCH, 2005, 13 (02): : 372 - 379
  • [5] Risk scoring in the assessment of cardiovascular risk
    Beswick, Andrew
    Brindle, Peter
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2006, 17 (04) : 375 - 386
  • [6] Obesity, survival, and hospital costs -: Findings from a screening project in Sweden
    Borg, S
    Persson, U
    Ödegaard, K
    Berglund, G
    Nilsson, JÅ
    Nilsson, PM
    [J]. VALUE IN HEALTH, 2005, 8 (05) : 562 - 571
  • [7] Estimating survival for cost-effectiveness analyses: A case study in atherothrombosis
    Caro, JJ
    Ishak, KJ
    Migliaccio-Walle, K
    [J]. VALUE IN HEALTH, 2004, 7 (05) : 627 - 635
  • [8] A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)
    Clarke, PM
    Gray, AM
    Briggs, A
    Farmer, AJ
    Fenn, P
    Stevens, RJ
    Matthews, DR
    Stratton, IM
    Holman, RR
    [J]. DIABETOLOGIA, 2004, 47 (10) : 1747 - 1759
  • [9] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [10] Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome - A summary of the evidence
    Ford, ES
    [J]. DIABETES CARE, 2005, 28 (07) : 1769 - 1778